This page includes information about Phase 3 studies that are currently underway to find a safe and effective vaccine to help prevent COVID-19. We identified the studies listed on this page using ClinicalTrials.Gov, a Web-based resource maintained by the National Library of Medicine at the National Institute of Health in the United States (US). The Food and Drug Administration (FDA) requires drug companies to register their studies in ClinicalTrials.Gov if they: are recruiting study participants in the US, are being conducted under an FDA investigational new drug application (INDA), or involve a drug manufactured in the US.

A total of 72 Phase 3 studies testing vaccines to help prevent COVID-19 were listed in ClinicalTrials.gov as of August 15, 2021. We have divided the studies into 2 tables. In both tables, studies that are being conducted at sites in the US are highlighted in yellow. Table 1 includes studies that involve vaccines specifically designed to help prevent COVID-19. Table 2 includes studies that involve vaccines developed to prevent other diseases. In these studies, the investigators will be testing whether the vaccine also helps prevent COVID-19.

Some of the studies in Table 1 are “event-driven”. That means that the investigators will analyze the data to determine if the vaccine they are testing helps prevent COVID-19 as soon as “enough” cases of COVID-19 occur in the people participating. They will be hoping that most of the cases occur among people who get the placebo vaccine. In studies that are event-driven, the investigators have to say how many cases are “enough” before they start the study. In the studies where this information is available, the number of cases needed ranges from 20 to 32. (See last column in Table 1.) When a study is being conducted in the middle of a pandemic and tens of thousands of people participate, it does not take long to reach this number of cases. That is why it only takes a few months to be able to estimate vaccine efficacy.

Table 1: Phase 3 studies that involve vaccines specifically designed to help prevent COVID-19. (On mobile devices, table is best viewed if device is held horizontally.)

Note: You can use the scroll bars to see more columns and rows. You can also use the search box to limit the studies listed to those that contain a specific text string (for example, mRNA).

Note: You can use the scroll bars to see more columns and rows. You can also use the search box to limit the studies listed to those that contain a specific text string (for example, mRNA).
0	Sponsor (Collaborators)	Vaccine	Vaccine Type	Doses	Link to Record in ClinicalTrial.Gov	Link to Full Study Protocol (Blueprint)	Protocol Updates	Start Date	# of People Participating	Countries Where People Are Being Recruited to Participate	How Long Participants Will Be Followed	Age Range of People Participating	Primary Efficacy Endpoint	# of Cases Needed to Assess Efficacy
1	BioNTech SE (Pfizer)	BNT162b2	mRNA	2 doses 3 weeks apart	https://clinicaltrials.gov/ct2/show/NCT04368728	https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf	Updated Protocol	APR-29-2020	29,481 originally; Increased to 43,998	United States, Argentina, Brazil, and Turkey	Up to 2 years	18 to 85 Years originally; Expanded to 12 to 85 Years	Laboratory confirmed symptomatic COVID-19	32 for first interim analysis; 164 for final analysis
2	BioNTech SE (Pfizer)	BNT162b2	mRNA	2 doses 3 weeks apart	NCT04754594			FEB-16-2021	4,000	United States	Enrolled at 24 to 34 weeks gestation; Followed for 4 weeks following delivery	18 Years and older	Serum antibody levels
3	ModernaTX, Inc. (BARDA, NIAID)	mRNA-1273	mRNA	2 doses 4 weeks apart	https://clinicaltrials.gov/ct2/show/NCT04470427	Protocol		JUL-27-2020	30,000	United States	Up to 2 years	18 Years and older	Laboratory-confirmed symptomatic COVID-19	53 for first interim analysis; 151 for final analysis
4	ModernaTX, Inc	mRNA-1273	mRNA	2 doses 4 weeks apart	NCT04649151			DEC-09-2020	3,000	United States	1 year	12 to 17 Years	Serum antibody levels
5	ModernaTX, Inc	mRNA-1273	mRNA	2 doses 4 weeks apart	NCT04796896			MAR-15-2021	6,750	United States	1 year	6 months to 11 years	Serum antibody levels
6	AstraZeneca (Iqvia Pty Ltd)	AZD1222 (Also known as ChAdOx1 nCoV-19)	Non-Replicating Viral Vector	2 doses 4 weeks apart	https://clinicaltrials.gov/ct2/show/NCT04516746	https://s3.amazonaws.com/ctr-med-7111/D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-cece903592b9/D8110C00001_CSP-v2.pdf		AUG-28-2020	30,000	United States	Up to 2 years	18 Years and older	Laboratory confirmed symptomatic COVID-19	75 for first interim analysis; 150 for final analysis
7	Janssen Vaccines & Prevention B.V. of Johnson & Johnson	JNJ-78436735 (Also known as Ad26.COV2.S)	Non-Replicating Viral Vector	1 dose	https://clinicaltrials.gov/ct2/show/NCT04505722	https://www.jnj.com/coronavirus/covid-19-phase-3-study-clinical-protocol		SEP-07-2020	60,000	United States, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, and Ukraine	Up to 2 years	18 Years and older	Laboratory confirmed moderate to severe/critical COVID-19	20 for first interim analysis; 154 for final analysis
8	Janssen Vaccines & Prevention B.V. of Johnson & Johnson	JNJ-78436735 (Also known as Ad26.COV2.S)	Non-Replicating Viral Vector	2 doses 8 weeks apart	https://clinicaltrials.gov/ct2/show/record/NCT04614948			NOV-15-2020	30,000	United States, Belgium, Colombia, France, Germany, Philippines, South Africa, Spain, and United Kingdom	Up to 2 years	18 Years and older	Laboratory confirmed moderate to severe/critical COVID-19	Information not available
9	Novavax (Dept US Health and Human Services)	NVXCoV2373 (Also known as SARS-CoV-2 rS With Matrix-M1 Adjuvant)	Protein Subunit	2 doses 3 weeks apart	https://clinicaltrials.gov/ct2/show/record/NCT04611802	Protocol		DEC-27-2020	30,000	United States, Mexico, and Puerto Rico	Up to 2 years	18 Years and older	Laboratory confirmed symptomatic COVID-19	72 for first interim analysis; 144 for final analysis
10	Inovio Pharmaceuticals	INO-4800	DNA	2 doses 3 weeks apart	NCT04642638			NOV-30-2020	6,178	United States	1 year	18 Years and older	Laboratory confirmed COVID-19
11	University of Oxford	AZD1222 (Also known as ChAdOx1 nCoV-19)	Non-Replicating Viral Vector	Testing single dose and 2-dose regimens	https://clinicaltrials.gov/show/NCT04400838			MAY-28-2020	12,330	United Kingdom	1 year	5 to 12 Years and 18 Years and older	Laboratory confirmed symptomatic COVID-19
12	University of Oxford	AZD1222 (Also known as ChAdOx1 nCoV-19)	Non-Replicating Viral Vector	Testing single dose and 2-dose regimens	https://clinicaltrials.gov/show/NCT04536051			JUN-02-2020	5,000	Brazil	1 year	18 Years and older	Laboratory confirmed symptomatic COVID-19
13	Gamaleya Res. Inst. of Epi. and Micro., Health Ministry of the Russian Fed. (Moscow city gov.; CRO: Crocus Medical BV)	Gam-COVID-Vac (Also known as Sputnik V)	Non-Replicating Viral Vector	2 doses 3 weeks apart	https://clinicaltrials.gov/show/NCT04530396			SEP-07-2020	40,000	Russian Federation	6 months	18 to 111 Years	Laboratory confirmed COVID-19
14	Gamaleya Res. Inst. of Epi. and Micro., Health Ministry of the Russian Fed. (Russian Direct Investment Fund; CRO: iPharma)	Gam-COVID-Vac (Also known as Sputnik V)	Non-Replicating Viral Vector	2 doses 3 weeks apart	https://clinicaltrials.gov/ct2/show/record/NCT04564716			SEP-28-2020	100	Belarus	6 months	18 to 60 Years	Laboratory confirmed COVID-19
15	Dr. Reddy's Laboratories (Gamaleya Res. Inst. of Epi. and Micro., Health Ministry of the Russian Fed.; RDIF; CRO: JSS Med Res India)	Gam-COVID-Vac (Also known as Sputnik V)	Non-Replicating Viral Vector	2 doses 3 weeks apart	NCT04640233			NOV-30-2020	1,500	India	6 months	18 Years and older	Serum antibody levels
16	Gamaleya Res. Inst. of Epi. and Micro., Health Ministry of the Russian Fed (Ministerio del Poder Popular para la Salud de la República Bolivariana de Venezuela)	Gam-COVID-Vac (Also known as Sputnik V)	Non-Replicating Viral Vector	2 doses 3 weeks apart	NCT04642339			NOV-2020 (Estimated)	2,000	Venezuela	6 months	18 Years and older	Serum antibody levels
17	Gamaleya Res Inst of Epi and Micro, Health Ministry of the Russian Fed (PCD-CRO)	Gam-COVID-Vac (Also known as Sputnik V)	Non-Replicating Viral Vector	2 doses 3 weeks apart	NCT04656613			DEC-2020 (Estimated)	1,000	Information not provided in ClinicalTrials.Gov	6 months	18 Years and older	Serum antibody levels
18	Gamaleya Res Inst of Epi and Micro, Health Ministry of the Russian Federation (RDIF, iPharma, City Gov of Moscow)	Sputnik Light	Non-Replicating Viral Vector	Not stated in ClinicalTrials.gov	NCT04741061			FEB-19-2021	6,000	Russia	6 months	18 Years and older	COVID-19
19	CanSino Biologics (Beijing Institute of Biotechnology)	Recombinant Novel Coronavirus vaccine (Adenovirus Type 5 Vector)	Non-Replicating Viral Vector	1 dose	https://clinicaltrials.gov/show/NCT04526990			SEP-15-2020	40,000	Pakistan	1 year	18 Years and older	Laboratory confirmed COVID-19
20	ReiThera Srl (Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani)	GRAd-COV2	Non-Replicating Viral Vector	Testing a single dose regimen and a 2 dose regimen with doses administered 3 weeks apart	NCT04791423			MAR-15-2021 (Estimated)	10,300	Italy	2 years	18 Years and older	Laboratory confirmed symptomatic COVID-19
21	Wits Health Consortium (Nat Dept Health South Africa; Nat Inst Communicable Dis, South Africa; KRISP; Fred Hutchinson Cancer Res Ctr; (HCRISA; Janssen Vaccines & Prevention; Bio Analytical Res Corp; Dis-Chem Pharmacy)	JNJ-78436735 (Also known as Ad26.COV2.S)	Non-Replicating Viral Vector	1 dose	NCT04838795			FEB-18-2021	500,000	South Africa	2 years	18 Years and older	Severe COVID, hospitalization, death
22	AstraZeneca (Iqvia Pty Ltd)	AZD2816	Non-Replicating Viral Vector	If previously vaccinated, 1 dose; If previously unvaccinated, 2 doses 4 weeks apart .	NCT04973449			JUN-27-20201	2,475	Brazil and United Kingdom	4 weeks	18 to 115 Years	Serum antibody levels
30	China National Biotec Group (G42 Healthcare; Abu Dhabi Health Services Co.; Wuhan Inst. of Biol. Prod.; Beijing Inst. of Biol. Prod.)	Inactivated SARS-CoV-2 Vaccine (Vero Cell), Wuhan AND Inactivated SARS-CoV-2 Vaccine (Vero Cell), Beijijg	Inactivated	2 doses 3 weeks apart	https://clinicaltrials.gov/show/NCT04510207			JUL-16-2020	45,000	Bahrain, Jordan, United Arab Emirates	6 months	18 Years and older	COVID-19
31	Universidad Peruana Cayetano Heredia (Universidad Nacional Mayor de San Marcos)	Inactivated SARS-CoV-2 Vaccine (Vero Cell), Wuhan AND Inactivated SARS-CoV-2 Vaccine (Vero Cell), Beijijg	Inactivated	2 doses (Time between doses not provided)	https://clinicaltrials.gov/ct2/show/record/NCT04612972			SEP-10-2020	6,000	Puru	1 year	18 Years and older	Laboratory confirmed COVID-19
32	Laboratorio Elea Phoenix S.A. (Beijing Inst. of Bio. Products; China National Biotec Group; The Huesped Foundation)	Inactivated SARS-CoV-2 Vaccine (Vero Cell), Beijijg	Inactivated	2 doses 3 weeks apart	https://clinicaltrials.gov/ct2/show/record/NCT04560881			SEP-16-2020	3,000	Argentina	1 year	18 to 85 Years	Confirmed COVID-19
33	Chinese Academy of Medical Sciences	Inactivated SARS-CoV-2 Vaccine (Vero Cell), manufactured by IMBCAMS	Inactivated	2 doses 2 weeks apart	NCT04659239			JAN-28-2021	34,020	Brazil and Malaysia	1 year	18 Years and older	Laboratory confirmed symptomatic COVID-19
34	Sinovac Research and Development Co., Ltd.	Coronavac	Inactivated	2 doses 2 weeks apart	https://clinicaltrials.gov/ct2/show/record/NCT04617483			OCT-31-2020	1,040	China	14 days after second vaccination	18 Years and older	Serum antibody levels
35	Butantan Institute (Sinovac Life Sciences)	Coronavac	Inactivated	2 doses 2 weeks apart	https://clinicaltrials.gov/show/NCT04456595			JUL-21-2020	8,870	Brazil	1 year	18 Years and older	Laboratory confirmed symptomatic COVID-19
36	PT Bio Farma (Sinovac Life Sciences)	Coronavac	Inactivated	2 doses 2 weeks apart	https://clinicaltrials.gov/show/NCT04508075			AUG-10-2020	1,620	Indonesia	6 months	18 to 59 Years	Laboratory-confirmed COVID-19
37	Pontificia Universidad Catolica de Chile (Ministry of Health, Chile; Sinovac Biotech)	Coronavac	Inactivated	2 doses 2 weeks apart	NCT04651790			NOV-27-2020	2,300	Chile	1 year	18 Years and older	Laboratory confirmed COVID-19
38	Health Institutes of Turkey	Coronavac	Inactivated	2 doses 2 weeks apart	https://clinicaltrials.gov/ct2/show/record/NCT04582344			SEP-14-2020	13,000	Turkey	1 year	18 to 59 Years	Laboratory confirmed symptomatic COVID-19
39	Bharat Biotech (Indian Council of Medical Researh, Iqvia)	BBV152	Inactivated	2 doses 4 weeks apart	NCT04641481			NOV-25-2020	25,800	India	1 year	18 Years and older	Laboratory confirmed symptomatic COVID-19	130 for final analysis
40	Res Inst Biolog Saf Prob (City polyclinic No. 4 UZO of Almaty; Clinic Int Inst Postgrad Educ; City Multidisc Hosp Health Department Akimat of Zhambyl Region)	QazCovid-in®	Inactivated	2 doses 3 weeks apart	NCT04691908			DEC-25-2020	3,000	Kazakhstan	6 months	18 Years and older	Serum antibody levels
41	Zagazig University	SARS-Cov-2 inactivated vaccine	Inactivated	2 doses 3 weeks apart	NCT04756271			FEB-11-2021	140	Information not provided in ClinicalTrials.Gov	21 days after second dose	18 Years and older	Serum antibody levels
42	Shenzhen Kangtai Biological Products (Beijing Minhai Biotechnology)	SARS-CoV-2 vaccine (Vero Cells)	Inactivated	2 doses 4 weeks apart	NCT04852705			MAY-2021	28,000	Information not provided in ClinicalTrials.Gov	1 year	18 Years and older	Symptomatic COVID-19
43	Valneva Austria GmbH	VLA2001	Inactivated	2 doses 4 weeks apart	NCT04864561			APR-26-2021	4,019	United Kingdom	1 year	18 Years and older	Serum antibody levels
50	University Hospital, Basel, Switzerland (Swiss National Science Foundation)	Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2)	mRNA	2 doses 4 weeks apart for Moderna; 2 doses 3 weeks apart for Pfizer	NCT04805125			APR 2021 (Estimated)	380	Switzerland	1 year	18 Years and older	Laboratory confirmed COVID-19; Serum antibody levels
51	CureVac AG	CVnCoV	mRNA	2 doses 4 weeks apart	NCT04838847			MAY-14-2021	180	Information not provided in ClinicalTrials.Gov	2 weeks	18 to 45 Years OR 65 Years and older	Serum antibody levels
52	CureVac AG	CVnCoV	mRNA	2 doses 4 weeks apart	NCT04652102			DEC-14-2020	36,500	Germany	1 year	18 Years and older	Laboratory confirmed COVID-19
53	CureVac AG	CVnCoV	mRNA	2 doses 4 weeks apart	NCT04674189			DEC-23-2020	2,520	Germany	1 year	18 Years and older	Serum antibody levels
54	Walvax Biotech (Abogen Biosciences, Yuxi Walvax Biotech)	SARS-CoV-2 mRNA vaccine	mRNA	2 doses 4 weeks apart	NCT04847102			MAY-28-2021	28,000	Information not provided in ClinicalTrials.Gov	1 year	18 Years and older	COVID-19
60	Clover Biopharmaceuticals AUS (Coalition for Epidemic Preparedness Innovations; Int Vaccine Inst.)	AS03-adjuvanted SCB-2019	Protein Subunit	2 doses 3 weeks apart	NCT04672395			DEC-2020 (Estimated)	34,000	Information not provided in ClinicalTrials.Gov	1 year	18 Years and older	Laboratory confirmed COVID-19
61	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd	ZF2001	Protein Subunit	Not stated in ClinicalTrials.gov	NCT04646590			DEC-16-2020	29,000	China (Other unspecified countries)	1 year	18 Years and older	COVID-19
62	Novavax	NVXCoV2373 (Also known as SARS-CoV-2 rS With Matrix-M1 Adjuvant)	Protein Subunit	2 doses 3 weeks apart	https://clinicaltrials.gov/ct2/show/study/NCT04583995	Protocol		SEP-28-2020	9,000	United Kingdom	1 year	18 to 84 Years	Laboratory confirmed symptomatic COVID-19
70	Medicago	CoVLP	Protein Based Virus-Like Particles	2 doses 3 weeks apart	NCT04636697			NOV-19-2020	30,612	Canada	1 year	18 Years and older	Laboratory confirmed symptomatic COVID-19
71	Covaxx (Diagnósticos da América S/A)	UB-612	Peptide Antigen-based	2 doses 4 weeks apart	NCT04683224			FEB-01-2021 (Estimated)	7,320	Information not provided in ClinicalTrials.Gov	2 years	18 Years and older	SARS-CoV-2 infection
72	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"	EpiVacCorona	Peptide Antigen-based	2 doses 3 to 4 weeks apart	NCT04780035			NOC-18-2020	3,000	Information not provided in ClinicalTrials.Gov	9 months	18 Years and older	Laboratory confirmed symptomatic COVID-19
73	NeuroRx, Inc. (Cromos, Iqvia Pty Ltd, Brilife Georgia, Israel Institute for Biological Research)	IIBR-100	Recombinant vesicular stomatitis virus (rVSV) vaccine	2 doses 4 weeks apart	NCT04990466			AUG-15-2021	550	Information not provided in ClinicalTrials.Gov	1 year	18 to 85 Years	Serum antibody levels
100	Pfizer	BNT162b2 (Alone and in combination with pneumococcal vaccine)	mRNA	1 booster dose administered to people who have previously received 2 doses of BNT162b2	NCT04887948			MAY-20-2021	582	United States	6 months	65 Years and older	Serum antibody levels
101	WestVac Biopharma (West China Hospital)	Recombinant COVID-19 vaccine (Sf9 cells)	Protein Subunit	3 doses 3 weeks apart	NCT04904471			JUN-18-2021	40,000	Indonesia, Kenya, Philippines	1 year	18 Years and older	Laboratory confirmed symptomatic COVID-19
102	Sanofi Pasteur (GlaxoSmithKline)	Monovalent SARS-CoV-2 vaccine AND Bivalent SARS-CoV-2 vaccine	Protein Subunit	2 doses 3 weeks apart	NCT04904549			MAY-26-2021	37,430	Colombia, Honduras, Japan, United States	1 year	18 Years and older	Laboratory confirmed symptomatic COVID-19
103	Nanogen Pharmaceutical Biotechnology Joint Stock Co.	Nanocovax	Protein Subunit	2 doses 4 weeks apart	NCT04922788			JUN-07-2021	13,000	Vietnam	1 year	18 Years and older	Laboratory confirmed COVID-19
104	Health Institutes of Turkey	TURKOVAC Compared to CoronaVac	Both vaccines are inactivated	2 doses 4 weeks apart	NCT04942405			JUN-21-2021	40,800	Turkey	8 months	18 to 55 Years	Laboratory confirmed symptomatic COVID-19
110	AnGes (Japan Agency for Medical Research and Development)	AG0302-COVID19	DNA	Testing 2 dosing regimens: 2 doses 2 weeks apart and 2 doses 4 weeks apart	NCT04655625			NOV-23-2020	500	Japan	1 year	18 Years and older	Serum antibody levels
111	International Vaccine Institute	BBIBP-CorV	Inactivated	2 doses + a booster dose; Time interval between doses not specified in ClinicalTrials.Gov	NCT04984408			OCT-01-2021 (Estimated)	8,825	Information not provided in ClinicalTrials.Gov	2 years	18 Years and older	Laboratory confirmed COVID-19
112	Sinovac Research and Development	CoronaVac	Inactivated	2 doses 4 weeks apart	NCT04992260			AUG-25-2021 (Estimated)	14,000	Chile	1 year	6 Months to 17 Years	Laboratory confirmed symptomatic COVID-19
113	Cinnagen (Vaxine Pty Ltd)	SpikoGen	Inactivated	2 doses 4 weeks apart	NCT05005559			AUG-07-2021	16,876	Iran, Islamic Republic	6 months	18 to 49 Years	Laboratory confirmed symptomatic COVID-19
114	Valneva Austria GmbH	VLA2102 Compared to VLA2001	Inactivated	Testing 2 doses 4 weeks apart	NCT04956224			AUG-09-2021	750	New Zealand	1 year	12 Years and older	Serum antibody levels
115

Table 2: Phase 3 studies that involve vaccines developed to prevent other diseases (On mobile devices, table is best viewed if device is held horizontally.)

Note: You can use the scroll bars to see more columns and rows. You can also use the search box to limit the studies listed to those that contain a specific text string (for example, Harvard).

Note: You can use the scroll bars to see more columns and rows. You can also use the search box to limit the studies listed to those that contain a specific text string (for example, Harvard).
Sponsor (Collaborators)	Vaccine	Vaccine Type	Doses	Link to Record in ClinicalTrial.Gov	Start Date	# of People Participating	Countries Where People Are Being Recruited to Participate	How Long Participants Will Be Followed	Age Range of People Participating	Primary Efficacy Endpoint	Pregnant Women Included?	Special Inclusion Criteria
Washington University School of Medicine (COVID -19 Therapeutics Accelerator)	Measles-Rubella or Measles-Mumps-Rubella II® vaccine	Attenuated virus	1 dose	https://clinicaltrials.gov/ct1/show/NCT4333731	SEP-04-2020	30,000	United States, Canada, Ghana, Ireland, Netherlands, South Africa, Uganda, United Kingdom, Zambia, and Zimbabwe	6 months	18 Years and older	Laboratory confirmed symptomatic COVID-19	Women who were pregnant at start of study were excluded. Not clear whether women who were breastfeeding could participate.	Limited to healthcare workers at facilities with a high risk of developing COVID-19 due exposure to infected patients
Kasr El Aini Hospital	Measles-Mumps-Rubella vaccine	Attenuated virus	1 dose	https://clinicaltrials.gov/show/NCT04357028	JUL-13-2020 (Estimated)	200	Egypt	6 months	18 to 50 Years	Laboratory confirmed symptomatic COVID-19	Women who were pregnant at start of study were excluded. Not clear whether women who were breastfeeding could participate.
NeuroActiva, Inc (Biomed Industries, Inc.)	Oral polio vaccine with/without NA-831	Attenuated poliovirus; NA-831 is an experimental drug that has shown promise in the treatment of Alzheimer's disease	2 doses	https://clinicaltrials.gov/ct2/show/NCT04540185	NOV-01-2020 Estimated	3,600	United States and New Zealand	Up to 2 years	18 Years and older	COVID-19	Women who were pregnant or breastfeeding at start of study were excluded.
Harvard Medical School (Texas Medical Research Associates, L.L.C.)	BCG vaccine (Used to prevent tuberculosis)	Attenuated virus	1 dose	https://clinicaltrials.gov/ct2/show/NCT04534803	SEP-1-2020 Estimated	2,100	United States	Up to 1 year	70 Years and older	Severe COVID-19	No (Based on age range of study participants)	Limited to residents of long term care facilities
Murdoch Children's Research Institute (Royal Children's Hospital)	BCG vaccine (Used to prevent tuberculosis)	Attenuated virus	1 dose	https://clinicaltrials.gov/show/NCT04327206	MAR-30-2020	10,078	Australia, Netherlands, Spain	1 year	18 Years and older	Laboratory confirmed symptomatic COVID-19; Severe COVID-19	Women who were pregnant at start of study were excluded. Not clear whether women who were breastfeeding could participate.	Limited to healthcare workers in direct contact with patients
Universidad de Antioquia	BCG vaccine (Used to prevent tuberculosis)	Attenuated virus	1 dose	https://clinicaltrials.gov/show/NCT04362124	APR-1-2020 (Estimated)	1,000	Colombia	1 year	18 to 65 Years	Confirmed or probable COVID-19	Women who were pregnant or breastfeeding at start of study were excluded.	Limited to healthcare workers at clinics and hospitals in direct contact with COVID-19 patients
Ain Shams University	BCG vaccine (Used to prevent tuberculosis)	Attenuated virus	1 dose	https://clinicaltrials.gov/show/NCT4350927	APR-20-2020 (Estimated)	900	Egypt	Up to 6 months	18 Years and older	Confirmed COVID-19	Women who were pregnant or breastfeeding at start of study were excluded.	Limited to healthcare workers at isolation hospitals
TASK Applied Science	BCG vaccine (Used to prevent tuberculosis)	Attenuated virus	1 dose	https://clinicaltrials.gov/show/NCT04379336	MAY-04-2020	500	South Africa	1 year	18 Years and older	Hospitalization due to COVID-19	Women who were pregnant or breastfeeding at start of study were excluded.	Limited to healthcare workers or other frontline staff likely to be in direct contact with COVID-19 patients
Assistance Publique - HÃ´pitaux de Paris	BCG vaccine (Used to prevent tuberculosis)	Attenuated virus	1 dose	https://clinicaltrials.gov/ct2/show/NCT04384549	MAY-20-2020	1,120	France	6 months	18 Years and older	Laboratory confirmed symptomatic COVID-19	Women who were pregnant or breastfeeding at start of study were excluded.	Limited to healthcare workers from hospitals in direct contact with COVID-19 patients
Hospital Universitario Dr. Jose E. Gonzalez	BCG vaccine (Used to prevent tuberculosis)	Attenuated virus	1 dose	https://clinicaltrials.gov/show/NCT04461379	JUL-21-2020	908	Mexico	6 months	18 Years and older	Laboratory confirmed symtomatic COVID-19	Women who were pregnant or breastfeeding at start of study were excluded.	Limited to healthcare workers in direct contact with COVID-19 patients
University Health Network, Toronto (Serum Institute of India; Max Planck Institute for Infection Biology; Verity Pharmaceuticals)	VPM1002 (Based on BCG Vaccine)	Attenuated virus	1 dose	https://clinicaltrials.gov/show/NCT04439045	JUN-24-2020	3,626	Canada	7 months	18 Years and older	Laboratory confirmed COVID-19	Women who were pregnant or breastfeeding at start of study were excluded.	Limited to front line workers defined as people involved in public safety, healthcare, public transportation, and food manufacturing
Henry M. Jackson Fdn Advancement Mil Med (Harvard Med Sch, Uniformed Services Univ Hlth Sci, US Dept of Defense, Immunization HealthCare Div, Defense Hlth Agency)	Tice® BCG (Merck; Used to prevent tuberculosis)	Attenuated virus	1 dose	NCT04632537	DEC-07-2020	550	United States	6 months	18 to 64 Years	Laboratory confirmed symtomatic COVID-19	Women who were pregnant or breastfeeding at start of study were excluded.	Limited to healthcare workers who are likely to care for patients with COVID-19
Hanna Czajka (Medical Research Agency - Agencja Badań Medycznych)	BCG vaccine (Used to prevent tuberculosis)	Attenuated virus	1 dose	NCT04648800	JUL-7-2020	1,000	Poland	12 weeks	25 Years and older	Health-threatening condition (cardiac arrest, shock, severe respiratory or renal failure, stroke/TIA)	Women who were pregnant at start of study were excluded. Not clear whether women who were breastfeeding could participate.	Healthcare professional
Fundacio Institut Germans Trias i Pujol	RUTI® vaccine (Used to prevent tuberculosis)	Non-Replicating Viral Vector	2 doses 2 weeks apart	https://clinicaltrials.gov/show/NCT04453488	JUL-30-2020 (Estimated)	315	Spain	4 months	18 Years and older	Laboratory-confirmed COVID-19	Women who were pregnant or breastfeeding at start of study were excluded.	Limited to healthcare workers in direct contact with patients who may have COVID-19

Share this: